

ARISTIDES ELIOPOULOS
BRIEF CURRICULUM VITAE

Date and Place of Birth: 12 July 1966, Athens, Greece
Citizenship: Greek and British
Address: Laboratory of Molecular & Cellular Biology,
Medical School,
University of Crete
Voutes, Heraklion, 71003, Greece
Tel: +30 2810 39 4565 or 4819
e-mail: eliopag@med.uoc.gr
URL: <http://mcb.med.uoc.gr>

EDUCATION & TRAINING

1986 - 1990 B.Sc. Chemistry, University of Athens, Greece

1991 - 1994 Ph.D Molecular Biology, Medical School, University of Crete, Heraklion, Crete, Greece and National Hellenic Research Foundation, Athens, Greece.
Title: *«Regulation of c-myc expression during differentiation of mouse erythroleukemic cells».*

1991 – 1992 (4 months) Visiting Ph.D student, Department of Pharmaceutical Biochemistry, Freie Universität Berlin, Germany.

1994 - 1995 Post-doctoral Research Fellow, Dept. of Clinical Oncology, University of Birmingham, Birmingham, UK.

1996 - 2000 Post-doctoral Research Fellow, Cancer Research UK Institute for Cancer Studies, Birmingham, UK.

2001 (9 months) Visiting scientist (sabbatical), Department of Immunology and Microbiology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, USA

2003 (2 months) Visiting scientist, Molecular Oncology Research Institute, Tufts-New England Medical Center, Boston, USA.

2011 (1 month) Visiting scientist, Liverpool Cancer Center, University of Liverpool, UK.

POSITIONS AND EMPLOYMENT

- 2012- present: Professor, Head of the Molecular & Cellular Biology Laboratory, University of Crete Medical School, Heraklion, Greece.
- 2009- present: Group Leader, Institute for Molecular Biology & Biotechnology – Foundation of Research Technology Hellas, Heraklion, Greece.
- 2005- 2012: Associate Professor, Head of Molecular & Cellular Biology Laboratory, University of Crete Medical School, Heraklion, Greece.
- 2000 - 2005: Group leader, Cancer Research UK Institute for Cancer Studies, Birmingham, UK.
- 1995 - 2000: Post-doctoral Research Fellow, Cancer Research UK Institute for Cancer Studies, Birmingham, UK.
- 1994 - 1995: Post-doctoral Research Fellow, University of Birmingham, Dept. of Clinical Oncology, Birmingham, UK.

FELLOWSHIPS & AWARDS

2000: Medical Research Council (MRC) Career Development Award, London, UK.

This is a highly competitive award given to junior scientists to establish new research groups in biomedicine. They are awarded following evaluation of a program proposal by international experts and interview of shortlisted candidates. The award provided funding for personnel and consumables for 4 years.

1999: Medical Research Council (MRC) Research Fellowship, London, UK.

This is a 3-year fellowship awarded with the same procedure as above to post-docs who are envisaged to lead research groups. The award provided personal salary and funding for consumables (*interrupted because of the Career Development Award*).

1990: PhD fellowship by the National Hellenic Research Foundation (Athens) following written exams and interview.

FUNDING

Title: *Epigenetic regulation of gut stem cells in Drosophila melanogaster.*

Coordinator: A. Eliopoulos

Funding Agency: Latsis Foundation

Total Budget: € 12,000

Budget for my team: € 12,000

Duration: 01/01/2015 – 31/12/2015

Title: *Exploiting molecular pathways of apoptotic cell death for the rational design of therapeutic strategies for colon cancer* (Contract N° 11ΣYN_1_485).

Coordinator: A. Eliopoulos

Funding Agency: General Secretariat of Research & Technology of Greece

Total Budget: € 908,333

Budget for my team: € 275,000

Duration: 01/05/2013 – 31/12/2015

Title: *TransPOT: Enhancing University of Crete Medical School Scientific Excellence and Translational Research Potential in Human Diseases* (Contract N° 285948).

Coordinator: A. Eliopoulos

Funding Agency: European Commission

Total Budget: € 3,050,000

Duration: 01/01/2012 – 30/06/2015

Title: *INFLA-CARE: Understanding inflammation-associated tumorigenesis for the rational design of novel anti-cancer therapeutic strategies.* (Contract N° 223151)

Coordinator: A. Eliopoulos

Funding Agency: European Commission (FP7)

Total Budget: € 12,000,000

Budget for my team: € 1,000,000

Duration: 01/01/2009 – 31/12/2012 (4 έτη)

Note: INFLA-CARE received the highest score among more than 100 proposals on cancer-related research in the second round of 2008 applications.

Title: *Apothrapy: CD40 ligand-based modalities for the treatment of solid tumours.*

Coordinator: A. Eliopoulos

Funding Agency: European Commission (FP6)

Total Budget: € 1,900,000

Budget for my team: € 457,740

Duration: 01/10/2006 – 30/09/2009

Title: *Molecular Mechanisms regulating the sensitivity of carcinoma cells to CD40 ligand-induced apoptosis and the cross-talk with the integrin network.*

Coordinator: A. Eliopoulos

Funding Agency: Association for International Cancer Research, UK

Total Budget: € 122,130
Budget for my team: € 122,130
Duration: 01/04/2006 – 30/03/2009
Note: This proposal was one of 66 applications funded by AICR among 485 (success rate 13.6%).

Title: *New technologies for the diagnosis of bladder cancer.*
Coordinator: Creta Interclinic Hospital
Funding Agency: General Secretariat of Research & Technology of Greece
Total Budget: € 120,000
Budget for my team: € 10,000 (+equipment)
Duration: 16/10/2006 – 15/06/2008

Title: *The CD40 pathway in carcinomas: regulation of apoptosis and therapeutic application.*
Coordinator: A. Eliopoulos
Funding Agency: Cancer Research UK
Total Budget: £ 240,000 (approx. € 260,000)
Budget for my team: £ 240,000 (approx. € 260,000)
Duration: 01/07/2004 – 30/06/2007

Title: *The role of Epstein-Barr virus-encoded latent genes in the pathogenesis of virus-associated tumours.*
Coordinator: L.S.Young
Funding Agency: Cancer Research UK
Total Budget: £ 900,000 (approx. € 1,150,000)
Budget for my team: approx. € 150,000
Duration: 01/05/2005 – 30/12/2010

Title: *Identification and characterisation of signal transduction pathways activated by EBV-encoded latent membrane protein-1.*
Coordinator: A. Eliopoulos
Funding Agency: MRC Career Development Award, UK
Total Budget: £ 312,000 (approx. € 330,000)
Budget for my team: approx. € 330,000
Duration: 01/10/2000 – 30/09/2004

Title: *The CD40 pathway in carcinomas: characterisation of pro-apoptotic pathways identifies novel therapeutic opportunities.*
Coordinator: A. Eliopoulos
Funding Agency: Cancer Research UK
Total Budget: £ 200,000 (approx. € 220,000)
Budget for my team: £ 200,000 (approx. € 220,000)

Duration: 01/07/2001 – 30/08/2004

Title: *Expression and function of the novel TNF receptor TRADE and its ligand in the human liver.*

Coordinator: S.C. Afford

Funding Agency: Genetics Institute, USA

Total Budget: \$ 85,000

Budget for my team: approx. \$ 15,000

Duration: 01/03/2001 – 27/02/2003

Title: *The role of CD40 in carcinomas.*

Coordinator: L.S.Young

Funding Agency: Cancer Research UK

Total Budget: £ 170,000 (approx. € 200,000)

Budget for my team: approx. € 100,000

Duration: 01/07/1998 – 30/06/2001

Title: *Identification of genes activated by CD40 and its C-terminus-interacting protein, TRAF3.*

Coordinator: A. Eliopoulos

Funding Agency: University of Birmingham Medical School Faculty Research Grant.

Total Budget: £ 2,000 (approx. € 2,400)

Budget for my team: approx. € 2,400

Duration: 1999

Title: *Regulation of CD40 and LMP1 signalling by interleukin 6.*

Coordinator: A. Eliopoulos

Funding Agency: University of Birmingham Medical School Faculty Research Grant/
E.B. Jones Bequest

Total Budget: £ 2,500 (approx. € 3,000)

Budget for my team: approx. € 3,000

Duration: 1998

REPRESENTATIVE RECENT PUBLICATIONS

- Vyrla D, Nikolaidis G, Oakley F, Perugorria MJ, Tsihchlis PN, Mann DA and Eliopoulos AG: TPL2 Kinase Is a Crucial Signaling Factor and Mediator of NKT Effector Cytokine Expression in Immune-Mediated Liver Injury. *J Immunol.* 2016, *in press*.
- Gkouskou KK, Ioannou M, Pavlopoulos GA, Georgila K, Siganou A, Nikolaidis G, Kanellis DC, Moore S, Papadakis KA, Kardassis D, Iliopoulos I, McDyer FA, Drakos E and Eliopoulos AG: Apolipoprotein A-I inhibits experimental colitis and colitis-propelled carcinogenesis. *Oncogene, in press*.
- Panagi M, Georgila K, Eliopoulos AG and Apidianakis Y: Constructing the intestinal holo'ome of inflammation-driven cancer: from flies and mice to humans. *Oncotarget, in press*.
- Doxaki C, Kampranis S, Eliopoulos AG, Spilianakis C and Tsatsanis C: Coordinated regulation of miR-155 and miR-146a genes during induction of endotoxin tolerance in macrophages. *J Immunol.* 2015 Dec 15;195(12):5750-61
- Kanellis DC, Bursac S, Tsihchlis PN, Volarevic S, Eliopoulos AG: Physical and functional interaction of the TPL2 kinase with nucleophosmin. *Oncogene* 2015; 34(19):2516-26.
- Vlahava VM, Eliopoulos AG, Sourvinos G: CD40 ligand exhibits a direct antiviral effect on Herpes Simplex Virus type-1 infection via a PI3K-dependent, autophagy-independent mechanism. *Cell Signal.* 2015; 27(6):1253-63
- Papanikolaou N, Pavlopoulos GA, Pafilis E, Theodosiou T, Schneider R, Satagopam VP, Ouzounis CA, Eliopoulos AG, Promponas VJ, Iliopoulos I: BioTextQuest(+): a knowledge integration platform for literature mining and concept discovery. *Bioinformatics.* 2014; 30(22):3249-56.
- Kepp O, Senovilla L, Vitale I, Vacchelli E, Adjemian S, Agostinis P, Apetoh L, Aranda F, Barnaba V, Bloy N, Bracci L, Breckpot K, Brough D, Buqué A, Castro MG, Cirone M, Colombo MI, Cremer I, Demaria S, Dini L, Eliopoulos AG, Faggioni A, et al: Consensus guidelines for the detection of immunogenic cell death. *Oncoimmunology.* 2014; 3(9):e955691.
- Gkouskou KK, Deligianni C, Tsatsanis C, Eliopoulos AG: The gut microbiota in mouse models of inflammatory bowel disease. *Front. Cell. Infect. Microbiol.* 2014; 4:28. (Review article).
- Liljenfeldt L, Gkirtzimanaki K, Vyrla D, Svensson E, Loskog AS, Eliopoulos AG: Enhanced therapeutic anti-tumor immunity induced by co-administration of 5-fluorouracil and adenovirus expressing CD40 ligand. *Cancer Immunol Immunother.* 2014; 63(3):273-82.
- Miliara S, Gkouskou KK, Sharp TV, Eliopoulos AG: SUMOylation is required for optimal TRAF3 signaling capacity. *PLoS One.* 2013 Nov 18;8(11):e80470.
- Gkirtzimanaki K, Gkouskou KK, Oleksiewicz U, Nikolaidis G, Vyrla D, Lontos M, Pelekanou V, Kanellis DC, Evangelou K, Stathopoulos EN, Field JK, Tsihchlis PN, Gorgoulis V, Liloglou

- T, Eliopoulos AG: TPL2 kinase is a suppressor of lung carcinogenesis. *Proc Natl Acad Sci U S A*. 2013 Apr 16;110(16):E1470-9.
- Moschonas A, Ioannou M & Eliopoulos AG: A feed-forward NF- κ B-driven molecular pathway regulates expression of IFN- β in CD40-stimulated carcinoma cells. *J. Immunol*. 2012 Jun 1;188(11):5521-7.
- Serebrennikova OB, Tsatsanis C, Mao C, Gounaris E, Ren W, Siracusa L, Eliopoulos AG, Khazaie K, and Tsihchlis PN: Tpl2 ablation promotes intestinal inflammation and tumorigenesis in Apc^{min} mice by inhibiting IL-10 secretion and Treg generation. *Proc. Natl. Acad. Sci. USA* 2012 May 1;109(18):E1082-91
- Diaconu I, Cerullo V, Hirvonen M, Escutenaire S, Ugolini M, Pesonen S, Bramante S, Parviainen S, Kanerva Anna, Loskog A, Eliopoulos AG, Pesonen S, Hemminki A: Immune response is an important aspect of the anti-tumor effect of an oncolytic adenovirus coding for CD40L. *Cancer Res*. 2012 May 1;72(9):2327-38.
- Sideridou M, Zakopoulou, R, Evangelou K, Lontos M, Kotsinas A, Rampakakis E, Gagos S, Kahata K, Grabusic K, Gkouskou K, Trougakos I, Kolettas E, Georgakilas AG, Volarevic S, Eliopoulos AG, Zannis-Hadjopoulos M, Moustakas A and Gorgoulis VG: Cdc6 acts as a “switch” at the *E-cadherin* locus linking transcriptional repression to activation of replication. *J. Cell Biol*. 2011, 195: 1123-1140.
- Knox PG, Davies CC, Ioannou M & Eliopoulos AG: The death kinase RIP1 links the immunoregulatory CD40 receptor to apoptotic signaling in carcinoma. *J. Cell Biol*. 2011, 192: 391-9.
- Loskog A & Eliopoulos AG: The Janus faces of CD40 in cancer. *Sem Immunol*. 2009, 21: 301-307. (Invited review for the Seminars in Immunology issue on ‘The Role of CD40 in Lymphocyte Homeostasis’; Guest Editor: Gail Bishop).
- Vardouli L, Lindqvist C, Vlahou K, Loskog AS, Eliopoulos AG: Adenovirus delivery of human CD40 ligand gene confers direct therapeutic effects on carcinomas. *Cancer Gene Ther*. 2009, 16: 848-60.
- Moschonas A, Kouraki M, Knox PG, Thymiakou E, Kardassis D & Eliopoulos AG: CD40 induces antigen transporter and immunoproteasome gene expression in carcinomas via the coordinated action of NF- κ B and of NF- κ B mediated *de novo* synthesis of IRF-1. *Mol. Cell Biol*. 2008, 28: 6208-6222.
- Eliopoulos AG: ‘Make and Brake’ in signaling (*Perspective*). *Science* 2008; 321:648-649.
- Eliopoulos AG, Das S, Tsihchlis PN. The tyrosine kinase SYK regulates TPL2 activation signals. *J Biol Chem*. 2006; 281: 1371-1380.
- Davies CC, Mak TW, Young LS, Eliopoulos AG. TRAF6 is required for TRAF2-dependent CD40 signal transduction in nonhemopoietic cells. *Mol Cell Biol*. 2005; 25:9806-19.
-

BIBLIOMETRIC**DATA**

Number of Publications	106
As 1st Author	22
As Corresponding Author	30
h-index	44 §
Total Citations	6336 §

§ *Source: Google Scholar, 24/06/2015*